Semaglutide activates only GLP-1 receptors, while tirzepatide is a dual agonist that also activates GIP receptors, typically producing slightly higher weight loss in trials
J Neurosci 21(20):81988209 Nakayama M, Uchimura K, Zhu RL, Nagayama T, Rose ME, Stetler RA, Isakson PC, Chen J et al (1998) Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia
Reduced Injury Recovery: Could reduce recovery time following injury, surgery, or physical exertion
PubMed 27
The number of glutathione IV sessions you need to see results depends on your specific health goal
The available evidence including the STEP 4 withdrawal trial (Rubino et al., JAMA 2021) shows most people regain weight when they stop GLP-1 therapy without a structured maintenance plan